Active
    Mainboard

    Corona Remedies Ltd

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    Corona Remedies Ltd IPO opened on 08 Dec 2025 and closed on 10 Dec 2025, with a price band of ₹1008–₹1,062 per share. The IPO had a lot size of 14 shares, requiring a minimum investment of ₹14,868 per lot at the upper price band. The issue size was ₹655.37 crore, and the shares get listed on 15 Dec 2025.

    Corona Remedies Ltd IPO Details

    Listing Date

    15 Dec 2025

    Bid Price

    ₹1008 - ₹1,062

    Lot Size

    14 Shares

    Minimum Investment

    ₹14,868 / Lot

    Issue Size

    ₹655.37 Cr

    Employee Discount

    ₹54 per share

    Key Dates to Track

        Here are the important dates you need to know in order to participate in this IPO

    tick

    Offer Start Date

    8th Dec

    tick

    Offer End Date

    10th Dec

    tick

    Allotment Date

    11th Dec

    tick

    Refund Initiation

    12th Dec

    tick

    Demat Transfer

    12th Dec

    tick

    Listing Date

    15th Dec

    About Corona Remedies Ltd IPO

    Incorporated in August 2004, Corona Remedies Limited operates as a pharmaceutical company with activities in the development, manufacturing, and marketing of branded formulations. The company’s product portfolio covers multiple therapeutic segments, including women’s healthcare, cardio-diabeto, pain management, urology, and other multispecialty areas. As of June 30, 2025, the portfolio consisted of 71 brands across these categories, including products in vitamins and minerals, nutrition, gastrointestinal, and respiratory segments. The company engages with healthcare professionals through a marketing and distribution network present across 22 states, supported by 2,671 medical representatives. This network is positioned to facilitate product availability in different regions of the Indian pharmaceutical market.
     

    Corona Remedies Limited operates two manufacturing facilities located in Gujarat, with a reported aggregate installed formulation capacity of 1,285.44 million units per annum. Based on available domestic sales data for MAT June 2025, the women’s healthcare segment accounted for 28.56% of sales at ₹4,080.26 million, cardio-diabeto products accounted for 23.38% at ₹3,339.96 million, pain management contributed 11.79% at ₹1,684.38 million, and the urology segment accounted for 4.53% at ₹646.65 million. These figures reflect the contribution of individual therapeutic segments within the company’s product basket. The information provided reflects publicly available disclosures and can be cross-checked with official filings for accuracy.

    Corona Remedies Ltd Shareholding Pattern

      Pre-Issue Post-Issue
    Promoter Group 72.5% 69%
    Public Group 27.5% 31%

    Corona Remedies Ltd IPO Reservation

    QIB Shares Offered 12,23,203 (19.82%)
    NII (HNI) Shares Offered 9,17,403 (14.87%)
    Retail Shares Offered 21,40,606 (34.69%)
    Anchor Investor Shares Offered 18,34,805 (29.73%)
    Total Shares Offered 61,71,102
    Total Shares With Anchor Investor 61,71,102

    Corona Remedies Ltd IPO Lot Size

    Application Lots Shares Amount
    Retail (Min) 1 14 ₹14,868
    Retail (Max) 13 182 ₹1,93,284
    S HNI (Min) 14 196 ₹2,08,152
    S HNI (Max) 67 938 ₹9,96,156
    B HNI (MIN) 68 952 ₹10,11,024

    Corona Remedies Ltd IPO Anchor Portion Size

    Bid Date December 05, 2025
    Shares Offered 19,59,116
    Anchor Investment Details 208.0581192

    Corona Remedies Ltd IPO registrar

    Bigshare Services Pvt Ltd
    Phone Number +91 22626 38200
    Email Id investor@bigshareonline.com
    Website www.bigshareonline.com

    Corona Remedies Ltd IPO Lead Manager

    1. JM Financial Ltd

    2. IIFL Capital Services Ltd

    3. Kotak Mahindra Capital Co. Ltd

    Corona Remedies Ltd Financial Information

    March 31, 2026 March 31, 2025 March 31, 2024
    Net Worth ₹746.86 Cr ₹606.34 Cr ₹480.41 Cr
    Reserves and Surplus ₹685.7 Cr ₹545.18 Cr ₹419.25 Cr
    Total Borrowing ₹142.86 Cr ₹62.7 Cr ₹134.14 Cr

    Strength of Corona Remedies Ltd

    • Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.
    • Demonstrated capabilities of building a diversified portfolio, including "engine" brands, in our targeted therapy areas.
    • Pan-India sales network and marketing strategy focused on the "middle of the pyramid" target market.
    • Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
    • Qualified, experienced and entrepreneurial management team supported by marquee investors.

    Risks Involved

    • The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.
    • Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
    • The company derive a significant majority of its revenue from the company operations within India (constituting 96.34% and 96.33% of the company revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for the company products in India, or if its fail to successfully expand into international markets, the company business, results of operations, financial conditions and cash flows may be adversely affected.
    • A significant portion of the company domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of the company domestic sales for MAT June 2025). Any adverse developments affecting its sales in these regions could has an adverse effect on the company business, results of operations, financial condition and cash flows.
    • 70.10% of Its domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect the company business, results of operations, financial condition and cash flows.
    • Its depend on third-party suppliers to procure the company raw materials and finished goods, with whom the company does not has long term contracts, with the company total purchases aggregating to 19.87% and 27.96% of its total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, the company relies on La Chandra Pharmalab Private Limited, its Associate and Group Company, for the supply of certain active pharmaceutical ingredients in the comapny women's healthcare therapeutic area. its cannot assure you that the company will be in a position to fully control or direct the operations of such suppliers to ensure an uninterrupted supply of raw materials and APIs.
    • As of June 30, 2025, with a portfolio of 71 brands, its held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If its unable to obtain trademarks for the company products and brands or protect other proprietary information, the company business, results of operations, financial condition and cash flows may be adversely affected.
    • The company required to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company operations. If its fail to obtain, maintain or renew the required licenses, permits and approvals, it may adversely affect the company business, results of operations, financial condition and cash flows.
    • Proceeds from the Offer will not be available to it.
    • As of June 30, 2025, its engaged 22 carrying and forwarding agents for the sale of the company products across the regions in which the company market its products, with the company five largest C&F agents contributing to 43.30% and 44.35% of Its revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025. The loss of the company C&F agents, the deterioration of their financial condition or prospects, a reduction in their demand for the company products or its inability to maintain and increase the number of the company arrangements for the distribution of its products could adversely affect the company business, results of operations, financial conditions and cash flows.
    Invest in IPOs with ease

    Sign-in to invest with your demat account, or set up a new demat account for free

    Industry Outlook of Corona Remedies IPO

    • The Indian domestic formulation segment in Financial Year 2025 reported an estimated market value of around ₹2.3 trillion, representing close to 2% of the global pharmaceutical market size.

    • The sector operates within a manufacturing ecosystem that includes production facilities with advanced technology and a specialised workforce engaged in pharmaceutical development.

    • Consumption within the domestic formulation market recorded a compound annual growth rate (CAGR) of about 9% during Financial Years 2020 to 2025, based on available sector data.

    • Market projections sourced from industry estimates indicate a possible CAGR range of 8–9% for the period leading to Financial Year 2030.

    • The estimated value range for the market by Financial Year 2030 has been placed between ₹3.3 trillion and ₹3.5 trillion in published assessments.

    • These projections reflect demand factors that include higher reported cases of long-duration health conditions, rising awareness levels, and wider access to healthcare services in India.


    Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Corona Remedies IPO.    

    Explore Other IPOs

    • Current IPOs
    • Upcoming IPOs
    • Closed IPOs
    • IPO Performance
    • All
    • MainBoard
    • SME
    DHAVAL PACKAGING LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹92.0 - 97.0
    IPO Size
    ₹36,36,00,000
    JUNIPER GREEN ENERGY LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹214.0 - 225.0
    IPO Size
    ₹17,99,99,98,976
    MV ELECTROSYSTEMS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹400.0 - 425.0
    IPO Size
    ₹2,90,00,00,000
    Bidding Period
    30th Jul 2026 - 8th Aug 2026
    Price Range
    ₹91.0 - 96.0
    IPO Size
    ₹27,65,00,000
    Bidding Period
    31st Jul 2026 - 8th Aug 2026
    Price Range
    ₹151.0 - 159.0
    IPO Size
    ₹39,04,00,000
    G V ELECTRICALS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    31st Jul 2026 - 8th Aug 2026
    Price Range
    ₹123.0 - 130.0
    IPO Size
    ₹42,25,00,000
    Bidding Period
    3rd Aug 2026 - 8th Aug 2026
    Price Range
    ₹257.0 - 270.0
    IPO Size
    ₹1,77,80,99,968
    AEGEUS TECHNOLOGIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    4th Aug 2026 - 8th Aug 2026
    Price Range
    ₹100.0 - 105.0
    IPO Size
    ₹23,70,99,984
    ARDEE INDUSTRIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    5th Aug 2026 - 8th Aug 2026
    Price Range
    ₹50.0 - 53.0
    IPO Size
    ₹4,25,87,00,032
    • All
    • MainBoard
    • SME
    LAPL Automotive Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    6th Aug 2026 - 8th Aug 2026
    Price Range
    ₹88.0 - 94.0
    IPO Size
    ₹32,40,00,000
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AceVector Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Advanced SysTek Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Advanta Enterprises Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Agilus Diagnostics Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Airox Technologies Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Ajay Poly Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Allchem Lifescience Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Annu Projects Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    AOne Steels India Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    APPL Containers Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Ardee Engineering Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Arjun Jewellers Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    Armee Infotech Limited IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    To Be Announced
    Price Range
    ₹0.0 - 0.0
    IPO Size
    ₹0
    NO ACTIVE IPO HERE
    • All
    • MainBoard
    • SME
    H R HYGIENE PRODUCTS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    29th Jul 2026 - 7th Jul 2026
    Price Range
    ₹83.0 - 88.0
    IPO Size
    ₹53,95,00,032
    Bidding Period
    29th Jul 2026 - 7th Jul 2026
    Price Range
    ₹560.0 - 590.0
    IPO Size
    ₹92,75,21,99,680
    Bidding Period
    28th Jul 2026 - 7th Jul 2026
    Price Range
    ₹285.0 - 301.0
    IPO Size
    ₹1,59,83,00,032
    Bidding Period
    27th Jul 2026 - 7th Jul 2026
    Price Range
    ₹65.0 - 69.0
    IPO Size
    ₹28,57,00,000
    ADVANCE TECHNOFORGE LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    27th Jul 2026 - 7th Jul 2026
    Price Range
    ₹95.0 - 95.0
    IPO Size
    ₹24,03,00,000
    Bidding Period
    24th Jul 2026 - 7th Jul 2026
    Price Range
    ₹123.0 - 133.0
    IPO Size
    ₹82,43,00,032
    LOHIA CORP LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Jul 2026 - 7th Jul 2026
    Price Range
    ₹404.0 - 425.0
    IPO Size
    ₹11,01,29,00,864
    INDOMIM LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Jul 2026 - 7th Jul 2026
    Price Range
    ₹461.0 - 485.0
    IPO Size
    ₹38,12,12,01,664
    XTRANET TECHNOLOGIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    23rd Jul 2026 - 7th Jul 2026
    Price Range
    ₹120.0 - 127.0
    IPO Size
    ₹1,66,80,00,000
    CUBE HIGHWAYS TRUST IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    22nd Jul 2026 - 7th Jul 2026
    Price Range
    ₹151.0 - 152.0
    IPO Size
    ₹49,99,99,98,976
    Bidding Period
    22nd Jul 2026 - 7th Jul 2026
    Price Range
    ₹66.0 - 70.0
    IPO Size
    ₹18,90,00,000
    METALIC TECHNOFORGE LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    21st Jul 2026 - 7th Jul 2026
    Price Range
    ₹72.0 - 77.0
    IPO Size
    ₹49,96,00,000
    GULF LLOYDS INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    20th Jul 2026 - 7th Jul 2026
    Price Range
    ₹100.0 - 100.0
    IPO Size
    ₹18,19,00,000
    Bidding Period
    17th Jul 2026 - 7th Jul 2026
    Price Range
    ₹402.0 - 424.0
    IPO Size
    ₹4,49,99,99,744
    SOTEFIN BHARAT LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    16th Jul 2026 - 7th Jul 2026
    Price Range
    ₹178.0 - 187.0
    IPO Size
    ₹89,76,00,000
    ALPINE TEXWORLD LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    14th Jul 2026 - 7th Jul 2026
    Price Range
    ₹100.0 - 105.0
    IPO Size
    ₹1,26,24,99,968
    Bidding Period
    14th Jul 2026 - 7th Jul 2026
    Price Range
    ₹315.0 - 331.0
    IPO Size
    ₹1,60,33,99,936
    SBI FUNDS MANAGEMENT LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    14th Jul 2026 - 7th Jul 2026
    Price Range
    ₹545.0 - 574.0
    IPO Size
    ₹97,95,32,02,176
    Bidding Period
    9th Jul 2026 - 7th Jul 2026
    Price Range
    ₹203.0 - 214.0
    IPO Size
    ₹7,42,00,00,256
    HAPPY STEELS LIMITED IPO
    icon
    SME IPO
    Early Access
    Bidding Period
    9th Jul 2026 - 7th Jul 2026
    Price Range
    ₹62.0 - 66.0
    IPO Size
    ₹25,08,00,000
    • All
    • MainBoard
    • SME
    Issue Prize
    133.00
    Listing Day Close
    126.55(-4.51%)
    LOHIA CORP LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    425.00
    Listing Day Close
    494.65(16.47%)
    INDOMIM LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    485.00
    Listing Day Close
    741.80(52.99%)
    XTRANET TECHNOLOGIES LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    127.00
    Listing Day Close
    124.80(-1.57%)
    CUBE HIGHWAYS TRUST IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    152.00
    Listing Day Close
    156.88(3.29%)
    Issue Prize
    70.00
    Listing Day Close
    126.35(80.00%)
    METALIC TECHNOFORGE LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    77.00
    Listing Day Close
    83.05(7.79%)
    GULF LLOYDS INDIA LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    100.00
    Listing Day Close
    95.00(-5.00%)
    Issue Prize
    424.00
    Listing Day Close
    528.50(24.76%)
    SOTEFIN BHARAT LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    187.00
    Listing Day Close
    215.25(14.97%)
    ALPINE TEXWORLD LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    105.00
    Listing Day Close
    99.75(-4.76%)
    Issue Prize
    331.00
    Listing Day Close
    660.30(99.40%)
    SBI FUNDS MANAGEMENT LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    574.00
    Listing Day Close
    609.90(6.27%)
    Issue Prize
    214.00
    Listing Day Close
    262.85(22.90%)
    HAPPY STEELS LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    66.00
    Listing Day Close
    68.50(4.55%)
    DEVSON CATALYST LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    118.00
    Listing Day Close
    205.95(74.58%)
    KUSUMGAR LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    419.00
    Listing Day Close
    604.45(44.15%)
    Issue Prize
    99.00
    Listing Day Close
    174.30(75.76%)
    KNACK PACKAGING LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    170.00
    Listing Day Close
    182.70(7.65%)
    KRATIKAL TECH LIMITED IPO
    icon
    SME IPO
    Early Access
    Issue Prize
    135.00
    Listing Day Close
    182.40(34.81%)

    Frequently Asked Questions

    What is Corona Remedies Ltd IPO?

    Answer Field

    Corona Remedies Ltd IPO is a Mainboard IPO of 61,71,102 equity shares of a face value of ₹10 aggregating up to ₹655.37 Crores. The issue is priced at ₹1008 to ₹1062 per share. The minimum order quantity is 14 Shares. The IPO opens on December 08, 2025, and closes on December 10, 2025. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

    When Corona Remedies Ltd IPO will open?

    Answer Field

    The Corona Remedies Ltd IPO opens on December 08, 2025 and closes on December 10, 2025.

    What is the lot size of Corona Remedies Ltd?

    Answer Field

    Corona Remedies Ltd lot size is 14 shares, and the minimum amount required is ₹14,868.

    How to apply for Corona Remedies Ltd IPO?

    Answer Field

    You can apply in Corona Remedies Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

    • Login to Bajaj Broking account App/Website & click on IPO
    • Enter the number of lots and price at which you wish to apply.
    • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
    • You will receive a mandate notification to block funds in your UPI app.
    • Approve the mandate request on your UPI and funds will be blocked.

    When is Corona Remedies Ltd IPO allotment?

    Answer Field

    The finalization of Basis of Allotment for Corona Remedies Ltd IPO will be done on December 11, 2025, and the allotted shares will be credited to your demat account by December 12, 2025.

    When is Corona Remedies Ltd IPO listing date?

    Answer Field

    The Corona Remedies Ltd listing date is December 15, 2025.

    Who is the registrar of Corona Remedies Ltd IPO?

    Answer Field

    The registrar of Corona Remedies Ltd IPO is Bigshare Services Pvt Ltd

    Which company is the book-running lead manager of the IPO?

    Answer Field

    JM Financial Ltd,IIFL Capital Services Ltd,Kotak Mahindra Capital Co. Ltd will be the book-running lead manager of this IPO.

    What is the fresh issue of Corona Remedies Ltd IPO?

    Answer Field

    The fresh issue size is ₹[-] Crores equity shares.

    What minimum lot size can retail subscribers subscribe to Corona Remedies Ltd?

    Answer Field

    Retail investors can subscribe to a minimum of one lot, 14 shares and ₹14,868 amount.

    How can I approve the UPI mandate request for Corona Remedies Ltd IPO?

    Answer Field

    To apply for Corona Remedies Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

    What is the price range of Corona Remedies Ltd?

    Answer Field

    The price of each Corona Remedies Ltd share will be ranging in between ₹1008 to ₹1062 per share.

    What is the cut-off time for the UPI mandate for Corona Remedies Ltd IPO?

    Answer Field

    The cut-off time for the UPI mandate confirmation is 5:00 PM, December 10, 2025.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |